Argent Biopharma Limited Director/PDMR Shareholding

RNS Number : 8288D

Argent Biopharma Limited

12 September 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

PDMR Notification

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), has been notified of the following transaction which took place on 10 September 2024 whereby, Roby Zomer (Argent BioPharma's Managing Director & CEO) purchased 1,258,500 fully paid ordinary shares in Company at a price of A$0.40 each via an off-market purchase.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Roby Zomer
2	Reason for the notification
(a)	Position		Managing Director and Chief Executive Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		Argent BioPharma Ltd
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU0000326647
(c)	Nature of transaction		Off-market purchase.
(d)	Currency	Price		Volume	Total
	AUD	0.40		1,258,500	$503,400
	Aggregated information
	AUD	0.40		1,258,500	$503,400
(e)	Date of transaction		10 September 2024
(f)	Place of transaction		Outside a trading venue

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Limited

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma Limited

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBSGDCDDBDGSB

Argent Biopharma (LSE:RGT)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024